UnitedHealth Group (UNH) Stock Forecast & Price Target

UnitedHealth Group is supported by unmatched scale in insurance and care delivery, with leadership positions in Medicare Advantage, Medicare PDP, and commercial coverage, plus Optum’s vertically integrated pharmacy, services, and analytics platform that broadens earnings power across the healthcare continuum. Its 2Q performance and raised 2026 targets reinforced a disciplined pricing strategy, strong cash generation, and improving visibility, while MA margin recovery, Optum operational gains, and stronger free cash flow show the core businesses can offset pressure in Commercial and selected Optum Health contracts. The balance sheet and robust capital deployment, including brisk repurchases and a higher dividend, add further support, while long-term earnings growth of 13-16% remains credible given the company’s ability to convert its 51 million-member scale into sustained margin expansion.

UnitedHealth Group is facing a negative fundamental setup because multiple core businesses are seeing margin pressure, with Optum Health’s long-term pretax margin target cut to 6-8% from 8-10% and Medicaid, Commercial/ACA, and Optum Rx all implied to face EBIT declines. UHC’s $86.02B in revenue and 4.6% operating margin were helped by Medicare, but Commercial cost trends are running above the assumed ~11% level, and the No Surprises Act is adding about 50bps of incremental trend through an expensive IDR process. The outlook is further weakened by execution, regulatory, reimbursement, and DOJ-investigation risks, plus expected membership decline of about 1.1M and no meaningful change in core trends looking to ’27.